Du forlater nå GSKs nettsider

Denne lenken tar deg til en nettside som ikke tilhører GSK. GSK er ikke ansvarlig for, går ikke god for og aksepterer intet ansvar for informasjon eller meninger på nettsteder til tredjeparter

Fortsett

Tilbake

Bestill møte med legemiddelkonsulent

Bestill materiell

 

E-postservice

How to prescribe Triumeq?

Go to Close Top

Once-daily TRIUMEQ makes dosing and administration simple for your patients

TRIUMEQ (dolutegravir/abacavir/lamivudine) is indicated for the treatment of Human Immunodeficiency Virus (HIV) infected adults and adolescents above 12 years of age weighing at least 40 kg. 1

Dosing recommendation 1

Triumeq dosing recommendation

Before initiating treatment with abacavir-containing products, screening for carriage of the HLA-B*5701 allele should be performed in any HIV-infected patient. Abacavir should not be used in patients known to carry the HLA-B*5701 allele. [1] Find out more on HLA-B*5701 screening here.

Dolutegravir should not be prescribed to women seeking to become pregnant. Women who can become pregnant should use effective contraception while taking dolutegravir 1

Convenient dosing 1,2

Convenient dosing of Triumeq

Triumeq should not be co-administered with polyvalent cation-containing antacids, supplements or multivitamins containing calcium, iron or magnesium. Triumeq is recommended to be administered 2 hours before or 6 hours after these medicinal products.
Dolutegravir increased metformin concentrations. A dose adjustment of metformin should be considered when starting and stopping coadministration of dolutegravir with metformin, to maintain glycaemic control. Metformin is eliminated renally and therefore it is of importance to monitor renal function when co-treated with dolutegravir.

For further information, please see Triumeq preparatomtale

*TRIUMEQ is a fixed-dose pill and should not be prescribed for patients requiring dose adjustments. Separate preparations of dolutegravir, abacavir, and lamivudine are available in cases where discontinuation or dose adjustment is required. 1

†TRIUMEQ is not recommended for patients with integrase inhibitor resistance.* 1
‡TRIUMEQ is not recommended for co-administration with efavirenz, nevirapine, rifampicin, or tipranavir/ritonavir. 1

*See How to prescribe Tivicay? for recommended dolutegravir dosing in patients with resistance to the integrase class.

References:

  1. TRIUMEQ (dolutegravir/abacavir/lamivudine) Summary of Product Characteristics.
  2. Kandel CE, Walmsley S. Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV. Drug Design, Development and Therapy. 2015:9 3547-3555.

TRIUMEQ trademark is owned by or licensed to the ViiV Healthcare group of companies.